Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 1688 results
October 2022
-
Key Release
Novartis maintient sa dynamique de croissance et confirme les prévisions de l’exercice 2022 pour le Groupe
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T3 en hausse de +4% tcc1 (-4% USD) Innovative Medicines (IM) : hausse du chiffre d’affaires de +4% tcc (-3% USD), soutenue par… -
Featured NewsNovartis Financial Results – Q3 2022 -
Key ReleaseNovartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH studyAd hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients…
-
Media ReleaseNovartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancerPhase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1Approximately 473,000 prostate cancer cases and…
-
Featured NewsWorld Sight Day 2022: Raising awareness on the importance of eye health -
Story People and Culture
In neuroscience, “an inflection point in knowledge and technology” -
Story Patient Perspectives
Let’s Talk About the C Word: Navigating a cancer diagnosis and the life beyond it with Leanne Pero
September 2022
-
Media ReleaseNovartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management eventTransformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the USAdvancing eight in-market brands with…
-
Key ReleaseNovartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patentAd hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its…
-
Media ReleaseSandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trialROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in…
-
Media ReleaseNovartis statement regarding competition authority investigation into assertion of a patentCompany confident to clarify legitimacy of its position and fully cooperating with authoritiesBasel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition…
-
Media ReleaseNovartis invests in early technical development capabilities for next-generation biotherapeuticsMulti-year investment of USD 300m will create integrated scientific environment to deliver on increasing growth and diversity of biotherapeutics portfolio Enhanced capacity and processes expected to…